Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $20.4 million versus the consensus estimate of $21.9 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.